Summary: ALK has developed a new adrenaline pen for emergency treatment
of
severe allergic reactions. In the months ahead, ALK expects to launch the
new
adrenaline pen on the first European markets as a substitute for the
company's
existing inlicensed product. Within the next few years, the new pen
is expected
to improve ALK's earnings from its adrenaline business. 

ALK
today announces that the company has developed a new and improved
adrenaline
auto-injector called JEXT®. The new product has been developed for
emergency
treatment of allergic reactions (anaphylaxis) caused by, for example,
foods or
bee stings. ALK expects the product to be approved by the European
health
authorities in the near future. 

JEXT® is expected to be available on the
first European markets on 1 January
2011. ALK holds the global product rights
and is planning to considerably
expand its geographical presence with
adrenaline products. 

ALK's current agreement on the sale and distribution
of an inlicensed
adrenaline product in 16 European countries will cease with
effect from 31
December 2010. In 2009, ALK's sales of the adrenaline product
accounted for
some DKK 200 million, equivalent to approximately 10% of total
sales. Earnings
from present sales of adrenaline products make only a minor
contribution to
ALK's total operating profits. With the introduction of JEXT®,
ALK expects to
improve the company's gross margin and substantially improve
earnings from the
business area within the next few years. 

ALK-Abelló
A/S


Jens Bager
President and CEO

Contact: Jens Bager, President and
CEO, tel. (+45) 4574 7576

Investor Relations: Per Plotnikof, tel. (+45) 4574
7527, mobile (+45) 2261 2525
Press: Martin Barlebo, tel. (+45) 4574 7901,
mobile (+45) 2064 1143


About anaphylaxis
Anaphylaxis is a severe allergic
reaction that develops rapidly and may lead to
death if not treated. The
allergic reaction can be triggered by foods or by bee
and wasp stings. The
symptoms can be itching, rash, swelling of the lips,
throat and tongue,
wheezing, shortness of breath, coughing and hoarseness,
nausea, vomiting,
stomach ache, headache, fear of death or unconsciousness. 

Treatment of
anaphylaxis is by means of adrenaline (epinephrine) injections, or
even
hospitalisation in some cases, and preventive measures. Patients at risk
of
developing anaphylaxis are recommended to carry a self-triggering
disposable
injector containing adrenaline (adrenaline auto-injector), which
must be used
immediately when symptoms of anaphylaxis appear. It is estimated
that in Europe
and the USA there are up to four million people carrying an
adrenaline
auto-injector. 

Since anaphylaxis has to be treated quickly and
effectively, it is important
that such adrenaline injectors are reliable,
simple to use and work properly
under all circumstances. 

About
JEXT®
JEXT® is a new and improved adrenaline pen that has been developed to
meet the
requirements of reliability and functionality. Furthermore, JEXT® has
a
considerably longer shelf-life than existing products. In the near
future,
JEXT® is expected to be approved in Europe for the emergency treatment
of
allergic reactions (anaphylaxis). JEXT® has been developed by ALK and
is
eventually expected to be launched worldwide. Until 31 December 2010, ALK
will
be retailing another, inlicensed adrenaline pen in a number of
European
countries (Austria, Belgium, Croatia, the Czech Republic, Denmark,
Finland,
Great Britain, Hungary, the Netherlands, Norway, Poland, Slovakia,
Slovenia,
Spain, Sweden and Switzerland). 

About ALK
ALK is a
research-driven global pharmaceutical company focusing on allergy
treatment,
prevention and diagnosis. ALK is the world leader in allergy
vaccination
(immunotherapy). The company has 1,700 employees with subsidiaries,
production
facilities and distributors worldwide. ALK is also part of a
strategic
partnership with Merck on tablet-based allergy vaccination in North
America.
The company is headquartered in Hørsholm, Denmark, and is listed on
NASDAQ OMX
Copenhagen A/S. Read more at www.alk-abello.com.